ReportWire

Tag: KRTX

  • Bristol Myers to Acquire RayzeBio in Deal Valued at $4.1 Billion

    Bristol Myers to Acquire RayzeBio in Deal Valued at $4.1 Billion

    [ad_1]

    Bristol Myers Squibb will acquire radiopharmaceutical therapeutics company RayzeBio for $62.50 a share in cash.

    Continue reading this article with a Barron’s subscription.

    View Options
    [ad_2]
    Source link